Sheldon H. Preskorn, MD

Sublingual Dexmedetomidine for Agitation in Schizophrenia

October 3, 2022

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or schizoaffective disorder.

Leslie Citrome, Sheldon H. Preskorn, John Lauriello, et al

Original Research

Esketamine Nasal Spray and Adverse Events Over Time

September 19, 2022

This study looked at the occurrence and severity of adverse events over time with esketamine nasal spray in MDD patients also receiving an oral antidepressant.

David J. Williamson, Jagadish P. Gogate, Jennifer K. Kern Sliwa, et al

Commentary

Creatinine Clearance Estimation, Package Inserts, and Therapeutic Drug Monitoring

November 26, 2019

This commentary discusses the findings and implications of a recent study by GruÌˆnder et al and also highlights the importance of following formulas to estimate creatinine clearance, reading package...

Sheldon H. Preskorn

Original Research

High False-Positive Rate of a Putative Biomarker Test to Aid in the Diagnosis of Schizophrenia

April 27, 2016

Cheryl A. Wehler, Sheldon H. Preskorn

Article

How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example

March 19, 2015

How do you avoid drug-drug interactions in your patients who are taking multiple medications? This article explains the process for assessing the risk of a drug causing or being...

Matthew Macaluso, Alice I. Nichols, Sheldon H. Preskorn

Letter to the Editor

Dr Preskorn Replies

October 15, 2013

Sheldon H. Preskorn

Original Research

Cytochrome P450 2D6 Phenoconversion Is Common in Patients Being Treated for Depression: Implications for Personalized Medicine

March 13, 2013

Sheldon H. Preskorn, Cecelia P. Kane, Kasia Lobello, et al

Commentary

Changes in the Product Label for Pimozide Illustrate Both the Promises and the Challenges of Personalized Medicine

September 15, 2012

Sheldon H. Preskorn

Original Research

Cytochrome P450 2D6 Phenotype Predicts Antidepressant Efficacy of Venlafaxine: A Secondary Analysis of 4 Studies in Major Depressive Disorder

April 13, 2010

Kasia W. Lobello, Sheldon H. Preskorn, Christine J. Guico-Pabia, et al

Academic Highlights

A Roadmap to Key Pharmacologic Principles in Using Antipsychotics: Application in Clinical Practice

April 15, 2009

Sheldon H. Preskorn

Original Research

The Impact of Calories and Fat Content of Meals on Oral Ziprasidone Absorption: A Randomized, Open-Label, Crossover Trial

October 21, 2008

Kuan Gandelman, Jeffrey A. Alderman, Paul Glue, et al

Letter to the Editor

Reply to "Intrinsic Activity of Aripiprazole Is Not 30% of Dopamine, But Only About 6% Under Ideal Antipsychotic Therapy"

May 11, 2008

Sheldon H. Preskorn

Sublingual Dexmedetomidine for Agitation in Schizophrenia

Esketamine Nasal Spray and Adverse Events Over Time

Creatinine Clearance Estimation, Package Inserts, and Therapeutic Drug Monitoring

High False-Positive Rate of a Putative Biomarker Test to Aid in the Diagnosis of Schizophrenia

How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example

Dr Preskorn Replies

Cytochrome P450 2D6 Phenoconversion Is Common in Patients Being Treated for Depression: Implications for Personalized Medicine

Changes in the Product Label for Pimozide Illustrate Both the Promises and the Challenges of Personalized Medicine

Cytochrome P450 2D6 Phenotype Predicts Antidepressant Efficacy of Venlafaxine: A Secondary Analysis of 4 Studies in Major Depressive Disorder

A Roadmap to Key Pharmacologic Principles in Using Antipsychotics: Application in Clinical Practice

The Impact of Calories and Fat Content of Meals on Oral Ziprasidone Absorption: A Randomized, Open-Label, Crossover Trial

Reply to "Intrinsic Activity of Aripiprazole Is Not 30% of Dopamine, But Only About 6% Under Ideal Antipsychotic Therapy"

ELSEWHERE:

FOLLOW US:

Sheldon H. Preskorn, MD

Sublingual Dexmedetomidine for Agitation in Schizophrenia

Esketamine Nasal Spray and Adverse Events Over Time

Creatinine Clearance Estimation, Package Inserts, and Therapeutic Drug Monitoring

High False-Positive Rate of a Putative Biomarker Test to Aid in the Diagnosis of Schizophrenia

How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example

Dr Preskorn Replies

Cytochrome P450 2D6 Phenoconversion Is Common in Patients Being Treated for Depression: Implications for Personalized Medicine

Changes in the Product Label for Pimozide Illustrate Both the Promises and the Challenges of Personalized Medicine

Cytochrome P450 2D6 Phenotype Predicts Antidepressant Efficacy of Venlafaxine: A Secondary Analysis of 4 Studies in Major Depressive Disorder

A Roadmap to Key Pharmacologic Principles in Using Antipsychotics: Application in Clinical Practice

The Impact of Calories and Fat Content of Meals on Oral Ziprasidone Absorption: A Randomized, Open-Label, Crossover Trial

Reply to "Intrinsic Activity of Aripiprazole Is Not 30% of Dopamine, But Only About 6% Under Ideal Antipsychotic Therapy"

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles